Navigation Links
VG Life Sciences, Inc. Announces the Initiation of IND-Enabling Animal Safety Studies
Date:11/4/2013

SANTA BARBARA, Calif., Nov. 4, 2013 /PRNewswire/ -- VG Life Sciences, Inc. is a publicly traded (VGLS) biotechnology company focused on developing treatments for patients suffering autoimmune and infectious diseases.

(Logo: http://photos.prnewswire.com/prnh/20131031/LA07859LOGO)

VG Life Sciences, Inc. has contracted ITR Laboratories Canada, Inc. to perform FDA IND enabling animal safety studies with its patented peptide VG1177. The studies will address the optimum route of administration and will provide key toxicological, pharmacological, genotoxicological, and toxicokinetic data for IND applications that VG Life Sciences, Inc. will submit for FDA review.

The inventor of VG1177 is Dr. Karen Newell Rogers, PhD at Texas A&M University School of Medicine and Chief Scientist at VG Life Sciences. "These animal safety studies mark an important step in advancing VG1177 from technology to treatment, and will provide key safety data in support of our coming clinical trials," said Dr. Newell Rogers.

Results from the studies are expected to conclude by July 2014.

"At our restructuring in July we identified three important initiatives that we needed to complete this year: raise additional capital, begin audited financials and start animal safety studies. We are proud we completed all these goals in less than 4 months. This sets the stage for key milestones in 2014," said John Tynan, VG Life Sciences' President and CEO. "Thus we are pleased to announce the start of this important pre-clinical study bringing us closer to monetize our intellectual property as outlined in our July 2013 Letter to Shareholders."

The VG1177 peptide prevents the survival of pro-inflammatory cells under conditions where inflammation is unwanted, thereby allowing the b
'/>"/>

SOURCE VG Life Sciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
3. KannaLife Sciences, Inc. Signs Exclusive License Agreement with National Institutes of Health Office of Technology Transfer (NIH-OTT)
4. Founded by Enlight Biosciences, KNODE partners with AstraZeneca and Other Partners
5. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
6. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
7. Pressure BioSciences, Inc. to Discuss Second Quarter 2012 Financial Results and Provide Business Update
8. Pressure BioSciences, Inc. Reports 70% Revenue Growth for Second Consecutive Quarter
9. QPS Acquires JSW Life Sciences, Largest Independent Contract Research Organization in Austria
10. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
11. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015  EP Global Communications, Inc. (Public OTC: EPGL) announced ... the Company about discussing EPGL,s electronic contact lens ... August 3, 2015.  Novartis CEO Joe Jimenez ... coming electronic contact lens market could be worth ... several years.  Novartis partnered with Google in 2014 ...
(Date:7/30/2015)... SOUTH PLAINFIELD, N.J., July 30, 2015 PTC ... corporate update and reported financial results for the second ... is progressing on many fronts across the organization.  We ... largest Duchenne muscular dystrophy clinical trial ever conducted with ... W. Peltz, Ph.D., Chief Executive Officer, PTC Therapeutics, Inc. ...
(Date:7/30/2015)...  Growth of the U.S. nonprescription market is primarily ... users to the OTC market. Due to an increasingly ... switch activity over the next five years with several ... brands entering the market into existing categories. ... (even those with low to moderate likelihood), the market ...
Breaking Medicine Technology:PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update 10Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 2Rx-to-OTC Switches -- Game Changers for the U.S. OTC Drugs Market through 2019, Sees Kline 3
... , ENGLEWOOD, Colo., Dec. 7 ... DoseEdge(TM), during this week,s ASHP Midyear Clinical Meeting (MCM). ... safety and pharmacy efficiency through the management of IV ... into current pharmacy practice and techniques, while providing a ...
... , CARLSBAD, Calif., Dec. 7 Genoptix, Inc. (Nasdaq: ... the Company,s participation at the Deutsche Bank 2009 MedTools Investor ... Mass. on December 9-10, 2009. , Genoptix,s EVP ... the Company on Wednesday, December 9, 2009. He will ...
Cached Medicine Technology:Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 2Baxa Features DoseEdge(TM) Pharmacy Workflow Manager at the ASHP Midyear Clinical Meeting 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned hot ... their new type of sod called Leisure Time(TM) zoysia . It's nicknamed LTZ(TM) ... To commemorate introduction of this new type of sod, Super-Sod is giving away red ...
(Date:7/31/2015)... Santa Clara, CA (PRWEB) , ... August 01, 2015 , ... Super Bowl 50 ... The National Football League’s biggest day each year is the Super Bowl. In the ... buildup that takes place from the host venue. The 2016 Super Bowl game will mark ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... July 31, 2015 , ... Last ... by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . , ... are customizable. The best part: whenever a product is purchased, the Meso Foundation ...
(Date:7/31/2015)... ... July 31, 2015 , ... Sculpted Contours Luxury Medical Aesthetics ... this week. Zeltiq Aesthetics released this new applicator in the United States as ... treating the outer thighs. The original applicator required a 2 hour treatment time. ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cheap 2016 Super Bowl Tickets at Levi's Stadium: Ticket Down Slashes Ticket Prices on Super Bowl 50 Tickets in Santa Clara, CA at Levi's Stadium 2Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3
... the FDA could be one of the most significant advances in ... say doctors involved in the research., ,Diabetes is a disease ... body (type 1 diabetes) or the body does not effectively use ... another hormone -- amylin -- to aid in the treatment of ...
... survey is a worldwide investigation of sociocultural and political ... network of social scientists. It includes questions about how ... their lives. ,It showed that average happiness has ... War II, although incomes have risen. ,The analysis ...
... death in many people, but previous research has not looked ... study focuses on depression in elderly people living in the ... ,The study, involved 250 participants in a community health program. ... of depression and then did so again at 18 months. ...
... care unit patients who receive a preventative round of antibiotics ... more likely to survive their ICU stay. // ... between ICU patients who were given antibiotics and those who ... antibiotics to kill harmful bacteria in the mouth, stomach, and ...
... be at risk for experiencing dangerous falls. ,Researchers studied more ... asked if they // had fallen in the last 12 months, ... medical attention for the falls. ,They also brought all ... history report. ,Results of the study show nearly three ...
... receives for breast cancer be putting her at higher ... ,Studies finds women who underwent simple mastectomy and radiotherapy ... had a radical mastectomy and no radiotherapy to later ... cancer rates were noted among a group of women ...
Cached Medicine News:Health News:ICU Survival can be improved by Antibiotic use 2
... Advanced Magnetics' contrast agent for use with MRI ... the first organ-specific MRI contrast agent to be ... agent is taken up by macrophages found only ... tumors. The liver is a principal site for ...
... new Contrast Agent for Ultrasonography ... stabilized SF6 microbubbles. The size ... 1 and 10 m, and ... and 5 x 108 per ...
... VISIPAQUE is the only isosmolar contrast medium (IOCM) ... to that of blood, VISIPAQUE was designed for ... only contrast medium formulated with sodium and calcium ... VISIPAQUE received FDA approval for use in children ...
... (iopromide) injection is a nonionic, iodinated, ... administration. Introduced in the U.S. in ... in Europe, ULTRAVIST today is ... has established a positive clinical experience ...
Medicine Products: